EDAP Highlights Business Progress in Europe

LYON, France, April 20, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the
global leader in therapeutic ultrasound, outlined the continuing progress of its
European business, in both HIFU and lithotripsy activities.

The company is continuing to see positive business progress, particularly in
Germany, France and Italy. In these countries, HIFU RPP activity is increasing
and experiencing strong adoption as a result of EDAP's and its direct
subsidiaries' aggressive communication and marketing programs to increase
physician and patient awareness. These initiatives have led to:

* Growing physician interest for HIFU,
* Significant increases in the number of treatments among existing
Ablatherm-HIFU sites,
* A 40% increase in the number of RPP treatments in Europe during the
first quarter,
* The opening of three new mobile RPP sites in German speaking
countries in the first quarter of 2009.
Judith Johannsen, Managing Director of EDAP TMS GmbH, commented: "I am very
enthusiastic about the growing interest for HIFU in Germany. Our communication
strategy is proving to be fully adapted and we believe there is significant
opportunity to continue to build on our initiatives and enhance awareness. Our
HIFU Symposium held in Stockholm during the EAU congress generated substantial
interest about the benefits of Ablatherm-HIFU among physicians, many of whom
enquired on our adapted pay-per-use RPP option. We clearly see a growing
interest in establishing HIFU as an option for prostate cancer treatment in
German prostate cancer centers."

The German EDAP TMS GmbH Lithotripsy business is also producing strong results
with three Sonolith I-sys sold within the last nine months, confirming EDAP's
position among the major players in the ESWL market, particularly with the
successful introduction of its High-end Sonolith I-sys lithotripter.

Marc Oczachowski, CEO of EDAP, commented: "I am particularly pleased with EDAP's
entry into the German lithotripsy market, which has always been tightly
controlled by German ESWL players over the last 25 years. With our Sonolith
I-sys high-end device, EDAP succeeded in establishing a respectable position in
Germany confirming the adoption of our superior electroconductive technology. I
am also very pleased with our growing HIFU RPP activity in Europe, confirming
our adapted and focused marketing strategy has been correctly implemented."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically
proven choice for high-intensity focused ultrasound (HIFU) treatment of
localized prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized prostate
cancer (stages T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy treatment. Approved
in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity
Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S.
Phase II/III clinical trial under an Investigational Device Exemption granted by
the FDA, the ENLIGHT US clinical Study. The Company also is developing this
technology for the potential treatment of certain other types of tumors. EDAP
TMS SA also produces and commercializes medical equipment for treatment of
urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For
more information on the company, please visit http://www.edap-tms.com,
http://www.hifu-planet.com and http://www.pcaresearch.com.

Forward-Looking Statements

In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties. These include
statements regarding the company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in these forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
company's filings with the Securities and Exchange Commission. Ablatherm-HIFU
treatment is in clinical trials, but not FDA-approved or marketed in the United
States.

-0-
CONTACT: EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com

The Ruth Group
Investors:
Nick Laudico
+1 646 536 7030
nlaudico@theruthgroup.com